UKUK

Shire gains on Firazyr approval

01.10.2011

Washington – British Shire plc gained more than 10% in late August on the London Stock Exchange after the US FDA approved Firazyr (icatibant) for acute attacks of hereditary angioedema. The compound was developed by Berlin-based Jerini AG, which was bought by Shire. Earlier in August, Shire had discontinued development of its Dermagraft cell therapy to treat venous leg ulcers after the engineered skin substitute missed a primary endpoint of complete healing in a Phase III trial. Shire had gained the product – which is marketed in the US for treating diabetic foot ulcers – through its US$750m acquisition of Advanced BioHealing Inc in June.

UKUK

19.08.2011

Brussels – While worldwide stock exchanges took a beating in late July and early August, European biotech stocks plunged even more. Stocks of majors like Roche, Novartis and GSK lost more than 10% in the first week of the month,...

Austria, UKUK

17.08.2011

London/Pasching –GE Healthcare vamps up its biopharmaceutical capabilities. The U.K. based unit of the U.S. technology giant General Electric, announced that it has reached an agreement to acquire the Austrian PAA Laboratories....

UKUK

16.08.2011

London – The International Multiple Sclerosis Genetics Consortium, led by the Universities of Cambridge and Oxford and funded by the Wellcome Trust, has identified 29 new genetic variations linked to multiple sclerosis (MS). The...

UKUK

16.08.2011

London – A consortium led by British gene medicince company Ark Therapeutics Group plc has received a EUR5.3m grant from the European Commission’s 7th Framework Programme to fund research to combine Ark’s technology covering...

UKUK

09.08.2011

London - Patents on biomarkers are necessary to encourage innovation and investment in the UK DNA diagnostics market. This is the conclusion of a report from the UK Human Genetics Commission. The paper "Intellectual Property and...

UKUK

15.07.2011

London/Rockville - GlaxoSmithKline and its American partner Human Genome Sciences, Inc. announced today that the European Commission has granted marketing authorisation for belimumab (Benlysta) as an add-on therapy in adult...

UKUK

07.07.2011

The British analytics specialist LGC Ltd. will buy its peer, KBioscience, for an undisclosed sum. The acquisition of KBioscience brings LGC expertise in genotyping services, chemistry and complements its genomic services...

Displaying results 31 to 40 out of 396

< Previous 31-40 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-uk/browse/3/article/shire-gains-on-firazyr-approval.html

Events

All Events

Stock list

All quotes

TOP

  • NOVACYT (F)4.98 EUR5.96%
  • STALLERGENES (F)53.50 EUR4.37%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • THROMBOGENICS (B)9.54 EUR-5.07%

TOP

  • WILEX (D)3.15 EUR314.5%
  • SANTHERA (CH)68.55 CHF90.4%
  • ADDEX (CH)4.08 CHF82.1%

FLOP

  • MERCK KGAA (D)65.43 EUR-48.6%
  • HYBRIGENICS (F)1.77 EUR-29.2%
  • PROSENSA (NL)9.81 USD-22.6%

TOP

  • SANTHERA (CH)68.55 CHF3489.0%
  • GW PHARMACEUTICALS (UK)427.00 GBP729.1%
  • PAION (D)2.79 EUR316.4%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-91.8%
  • THROMBOGENICS (B)9.54 EUR-69.5%

No liability assumed, Date: 25.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products